Mandated Benefits Review - Senate Bill 1198 - Submissions

The Insurance Federation of Pennsylvania (John R. Doubman, Secretary & Counsel)

  1. Statement addressing Section 9 requirements and opposing Senate Bill 1198.
  2. Copy of Senate Bill 1334, Session of 1995.
  3. Copy of the Federation's initial submission opposing Senate Bill 1334, dated April 29, 1996.
  4. Copy of the Federation's second submission opposing Senate Bill 1334, dated June 12, 1996.
  5. Testimony of George Grob, Deputy Inspector General for Evaluation and Inspections, U.S. Department of Health and Human Services. "Institutional Review Boards (IRBs): A System in Jeopardy?"
  6. McGinley L. "System for Conducting Clinical Trials On Patients Needs Reform, Report Says." Wall Street Journal. June 1, 1998. B5.
  7. Pear R. "Study Finds Risks for Patients in Drug Trials." The New York Times. May 30, 1998. A9.

Managed Care Association of Pennsylvania (Kimberly J. Kockler, Executive Director)

  1. Statement addressing Section 9 requirements.
  2. "Understanding Clinical Trials" on the National Cancer Institute website.
  3. "Selected causes of death 1996." Central Pennsylvania Business Journal.
  4. "Ineffective review boards jeopardize patient safety." USA Today. June 8, 1998.
  5. Ziegler J. "Who will support clinical research?" The State of Health Care in America. 1998. 60-61.
  6. Summary of Rhode Island House Bill 05062.
  7. "Georgia Children's Cancer Law Takes Effect" on the National Cancer Institute website.
  8. "Maryland Law Covers Clinical Trials" on the National Cancer Institute website.

Highmark (Bruce R. Hironimus, Vice President of Government Affairs)

  1. Cover Letter
  2. "Mandated Benefits Submission to the Pennsylvania Health Care Cost Containment Council: Senate Bill 1998 Cancer Clinical Trial Services Mandate."
  3. "1998 Facts figures." American Cancer Society website. http://www.cancer.org/staqtistics/cff98/graphicaldata.htm#enccbs.
  4. Cooper PF, Schone BS. "More Offers, Fewer Takers For Employment-Based Health Insurance: 1987 And 1996." Health Affairs. 16(6): 142-149. 1997.
  5. National Center for Policy Analysis. "The Cost of Health Insurance Mandates." Brief Analysis No. 237. August 1997.
  6. Ader M. "Investigational Treatments: Coverage, Controversy, and Consensus." Annals of Health Law. 5: 45-60. 1996.
  7. Beebe DB, Rosenfeld AB, Collins N. "An Approach to Decisions About Coverage of Investigational Treatments." HMO Practice. 11(2): 65-67. 1997.
  8. Bennett CL, Golub R, Waters TM, Tallman MS, Rowe JM. "Economic Analyses of Phase III Cooperative Cancer Groups Clinical Trials: Are They Feasible?" Cancer Investigation. 15(3): 227-236. 1997.
  9. Monaco GP, Goldschmidt P. "What Is Proper Cancer Care in the Era of Managed Care?"" Oncology. 11(1): 65-78. 1997.
  10. American Society of Clinical Oncology. "Critical Role of Phase I Clinical Trials in Cancer Treatment." Journal of Clinical Oncology. 15(2): 853-859. 1997.
  11. Meyer H. "Forward Motion On Medical Advances." Hospitals and Health Networks. May 5, 1996. 55-56.
  12. Pennsylvania Economy League, Capital Division. "Employer Health Care Costs - A Comparative Study of its Role in Pennsylvania's Business Climate." April, 1996.

Dr. John H. Glick, Dr. Ronald B. Herberman, and Dr. Robert C. Young (Directors of University of Pennsylvania Cancer Center, University of Pittsburgh Cancer Institute, and Fox Chase Cancer Center respectively)

  1. Letter in support of Senate Bill 1198 referring to their submissions for Senate Bill 1334.

Rohm and Haas Company (Lois C. Morris, Manager, Health Care & Disability Programs)

  1. Letter opposing health care mandates including those proposed in Senate Bill 1198.

Independence Blue Cross (Mary Ellen McMillen, Vice President, Legislative Affairs)

  1. Information opposing mandates in general.
  2. Employee Benefit Research Institute. "Trends in Health Insurance Coverage." EBRI Issue Brief. May 1997.

AFLAC - The American Family Life Assurance Company of Columbus (Richard J. Gmerek and Elvira O. Guida of the Law Offices of Maley Williamson, Hayden & Gmerek)

  1. Cover letter.
  2. "Statement of AFLAC Regarding the Health Care Cost Containment Council's Review of Senate Bill 1198."

Association of Community Cancer Centers (James W. Young, Director for State Societies and Government Relations)

  1. Letter supporting Senate Bill 1198.
  2. "Patient Care Costs For Clinical Trials: Why They Should Be Covered By Third-Party Payers." White Paper.

PhRMA

  1. "Comments Of The Pharmaceutical Research And Manufacturers Of America (PhRMA) Before The Pennsylvania Health Care Cost Containment Council Regarding Coverage Of Patient Costs Associated With Cancer Clinical Trials."